Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Complement-dependent cytotoxicity (CDC) is a biological mechanism by which the immune system destroys target cells, such as bacteria, virus-infected cells, or tumor cells. This process is initiated when antibodies—primarily IgG1, IgG3, and IgM—isotypes—bind to antigens on the surface of a target cell. The Fc region of these antibodies then interacts with C1q, the first component of the classical complement pathway. This triggers a cascade that leads to the assembly of the membrane attack complex (MAC), resulting in pore formation in the cell membrane and subsequent lysis or death of the target cell.
Antibody-mediated complement activation leading to MAC formation and cell lysis
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Complement-Dependent Cytotoxicity (None).